The Role of Medical Imaging in light of the Personalisation of Medicine

SMi's 10th annual oncology imaging conference, taking place on the 12-13 March in London, will provide comprehensive insights into the usage of imaging in clinical trials, giving delegates access to the latest information, legislation and case studies across the industry from innovators including Roche Diagnostics, Novartis and GSK, among others.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
In an age of personalised medicine, technique and practice need to be aligned

London (PRWEB UK) 2 February 2014

One of the driving forces behind the increasing commoditisation of the specialty is the lack of communication between radiologists and clinicians, according to a former senior radiology resident at the University of California. Ninety percent agreed that a strong clinician-radiologist relationship helps patient care, and 95 percent said they wanted radiology residents to pair with clinical teams on rounds in the future.
(Source: FierceMedicalImaging.com, 3 reasons to invite radiology residents on rounds, 2013)

In an age of personalised medicine, technique and practice need to be aligned. Creating and developing imaging strategies to drive both drug development and the delivery for correct treatment is key.

SMi's 10th annual imaging conference will provide attendees with a comprehensive insight into the industry and its future. We will be considering the current landscape of personalised imaging within the field of oncology, as research suggests healthcare that is inherently more ‘personal’ is the way forward. Informative imaging strategies for success will be a highlight for our event, as well as the exploration of current and future legislation and its impact on imaging. The use of imaging in clinical trials will also be examined and discussed together with developing new imaging agents.

Event highlights at SMi's 10th annual Imaging conference include:

  • New opportunities for cost-effective imaging management
  • New alternatives to expensive independent reviews – hear from globally recognised experts
  • Discuss case studies, challenges and opportunities in imaging guidelines featuring Novartis and GSK
  • Gain an in-depth insight into the challenges of imaging in Europe
  • Evaluate the power of imaging strategically

Speaker Panel includes:

  • Dr Azeem Saleem, Head of Oncology Applications, Imanova Centre for Imaging Sciences
  • Lori Dodd, PhD, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, US National Institutes of Health
  • Dr Marijn Vlaming, Research Scientist, TNO
  • Prash Krishna, Global Clinical Leader - Oncology, Novartis
  • Pallavi Chaturvedi, Imaging Project Manager, GSK Vesalius Imaging
  • Francois Lassailly, Head of in Vivo Imaging, Cancer Research UK
  • Dr Malcom Barratt-Johnson, Managing Director, PharmaMedic Consultancy Ltd

To view the full speaker line-up and conference programme, visit http://www.smi-online.co.uk/2014cancer-imaging27.asp.

Pharmacokinetics Pre-Conference Workshop | Led by Dr Marijn Vlaming, Research Scientist, TNO | 11th March 2014, London, UK
In this workshop various non- or minimally invasive methods to study pharmacokinetics in preclinical (in vitro and in vivo) and clinical settings will be presented. We will further describe methods to translate preclinical data to the situation in humans and options to obtain relevant data from humans early in the drug development process.


Contact